Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report

被引：0
|
作者：
Barot, Hasti [1 ]
Evans, Joanne [1 ]
Mohammed, Waleed [1 ]
Power, Danielle [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, London, England
来源：
LUNG CANCER | 2022年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [1] Sotorasib in KRAS p.G12C-mutated NSCLC
    Gassa, Asmae
    Oezkan, Filiz
    Bruns, Christiane
    Schmidt, Thomas
    Alakus, Hakan
    ONKOLOGE, 2021, 27 (10): : 1031 - 1032
  • [2] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
    Patel, Sandip P.
    ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
  • [3] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
    Fakih, Marwan G.
    Salvatore, Lisa
    Esaki, Taito
    Modest, Dominik P.
    Lopez-Bravo, David P.
    Taieb, Julien
    Karamouzis, Michalis V.
    Ruiz-Garcia, Erika
    Kim, Tae-Won
    Kuboki, Yasutoshi
    Meriggi, Fausto
    Cunningham, David
    Yeh, Kun-Huei
    Chan, Emily
    Chao, Joseph
    Saportas, Yaneth
    Tran, Qui
    Cremolini, Chiara
    Pietrantonio, Filippo
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2125 - 2139
  • [4] Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
    Jiang, Yanfang
    Zhang, Lei
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : e43 - e43
  • [5] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
    Pinto, L. Masfarre
    Rocha, P.
    Clave, S.
    Gorro, N. Navarro
    Sanchez, I.
    Giner, M.
    Lloret, A. Corbera
    Garcia, A. Taus
    Parreira, A. S. D. F. M.
    Paricio, B. Bellosillo
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
  • [6] Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis
    Schuler, M.
    Li, B. T.
    Skoulidis, F.
    Falchook, G.
    Sacher, A.
    Velcheti, V.
    Dy, G. K.
    Price, T.
    Borghaei, H.
    Kato, T.
    Takahashi, T.
    Spira, A.
    Ramalingam, S.
    Besse, B.
    Barlesi, F.
    Tran, Q.
    Henary, H.
    Ngarmchamnanrith, G.
    Govindan, R.
    Wolf, J.
    PNEUMOLOGIE, 2021, 75 : S38 - S38
  • [7] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
    Reactions Weekly, 2025, 2045 (1) : 6 - 6
  • [8] FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
    Nakajima, Erica C.
    Drezner, Nicole
    Li, Xiaoxue
    Mishra-Kalyani, Pallavi S.
    Liu, Yajun
    Zhao, Hong
    Bi, Youwei
    Liu, Jiang
    Rahman, Atiqur
    Wearne, Emily
    Ojofeitimi, Idara
    Hotaki, Lauren Tesh
    Spillman, Dianne
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1482 - 1486
  • [9] A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience
    Seiwerth, F.
    Bitar, L.
    Franolic, I. Lukic
    Sajnic, A.
    Jakopovic, M.
    Samarzija, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S426 - S426
  • [10] Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report
    Vitale, Antonio
    Vita, Emanuele
    Stefani, Alessio
    Cancellieri, Alessandra
    Lococo, Filippo
    Tortora, Giampaolo
    Bria, Emilio
    ONCOLOGIST, 2025, 30 (03):
12345